Abstract
Importance Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in young children. RSV largely disappeared in 2020 due to precautions taken because of the COVID-19 pandemic. Projecting the timing and intensity of the re-emergence of RSV and the age groups affected is crucial for planning for the administration of prophylactic antibodies and anticipating hospital capacity.
Objective To project the potential timing and intensity of re-emergent RSV epidemics in different age groups.
Design, Setting, Participants Mathematical models were used to reproduce the annual RSV epidemics before the COVID-19 pandemic in New York and California. These models were modified to project the trajectory of RSV epidemics in 2020-2025 under different scenarios with varying stringency of mitigation measures for SARS-CoV-2: 1) constant low RSV transmission rate from March 2020 to March 2021; 2) an immediate decrease in RSV transmission in March 2020 followed by a gradual increase in transmission until April 2021; 3) a decrease in non-household contacts from April to July 2020. Simulations also evaluated factors likely to impact the re-emergence of RSV epidemics, including introduction of virus from out-of-state sources and decreased transplacentally-acquired immunity in infants.
Main Outcomes and Measures The primary outcome of this study was defined as the predicted number of RSV hospitalizations each month in the entire population. Secondary outcomes included the age distribution of hospitalizations among children <5 years of age, incidence of any RSV infection, and incidence of RSV lower respiratory tract infection (LRI).
Results In the 2021-2022 RSV season, we expect that the lifting of mitigation measures and build-up of susceptibility will lead to a larger-than-normal RSV outbreak. We predict an earlier-than-usual onset in the upcoming RSV season if there is substantial external introduction of RSV. Among children 1-4 years of age, the incidence of RSV infections could be twice that of a typical RSV season, with infants <6 months of age having the greatest seasonal increase in the incidence of both severe RSV LRIs and hospitalizations.
Conclusions and Relevance Pediatric departments, including pediatric intensive care units, should be alert to large RSV outbreaks. Enhanced surveillance is required for both prophylaxis administration and hospital capacity management.
Competing Interest Statement
VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial virus. DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for work unrelated to this manuscript and is Principal Investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. L.J.B. reports grants from AbbVie, MedImmune, Janssen, Pfizer, MeMed, and the Bill & Melinda Gates Foundation. Funders had no role in design, interpretation, and reporting of this study. All other authors report no relevant conflicts.
Funding Statement
DMW and VEP acknowledge support from grants R01AI137093 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. EDS was supported, in part, by grants number UL1TR000142 and KL2-TR001862 from the National Center for Advancing Translational Science (NCATS) at the National Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was deemed exempt under 45CFR46.104 (4)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The demographic that support the findings of this study are publicly available from the American Community Survey of the U.S. Census Bureau. The hospitalization data are not available publicly but can be obtained upon signing a data use agreement with the Agency for Healthcare Research and Quality.RSV surveillance data for California (2009-2018) can be obtained from the Immunization Branch, California Department of Public Health.
